EDSA
Edesa Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$4.89
+2.73%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.2x
Market Cap
$47.14M
MomentumView details →
1D Return
+2.73%
YTD Return
+244.01%
RSI (14)
44.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.2x
Market Cap
$47.14M
RSI (14)
44.7
MomentumView details →
1D Return
+2.73%
YTD Return
+244.01%
SummaryUpdated Jun 1, 2026
Edesa Biotech, Inc. (NASDAQ:EDSA) is a Canadian biopharmaceutical company founded in 2015 and headquartered in Markham, Ontario. The company went public in 2010 and focuses on acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases. As a clinical-stage biotechnology firm, Edesa operates without generating revenue from product sales, instead relying on funding to advance its drug candidates through various phases of clinical trials toward potential regulatory approval and commercialization.
Similar companies
Latest newsMore news →
Edesa Biotech announced the commencement of an underwritten public offering of its common shares (or pre-funded warrants in lieu thereof) and accompanying common share warrants, with a 30-day option for underwriters to purchase up to 15% additional shares and warrants.16d agoEdesa Biotech reported financial results for the three and nine months ended June 30, 2026.22d ago